Portfolio

Our portfolio companies are developing important therapies for unmet medical needs. Our deep network of leading academic and industry executives helps generate some of the most promising healthcare deals led by top entrepreneurs.

The human approach to oncology

Learn More Visit Site

Developing cancer immunotherapeutics based on new insights into the tumor microenvironment

Learn More Visit Site

Antibody therapeutics addressing serious unmet medical needs

Learn More Visit Site

Developing transformative immuno-stimulatory medicines to unleash a powerful attack on cancer

Learn More Vsit Site

Developing novel T cell therapeutics in cancer

Learn More Visit Site

Addressing the bottlenecks associated with next generation sequencing in translational research by offering a robust platform for targeted sequencing applications

Learn More Visit Site

Manipulating metabolism to develop disease modifying therapeutics for immuno-oncology and immuno-inflammation

Learn More Visit Site

Developing a new class of medicines to treat cancer & other debilitating diseases

Learn More Visit Site

Seeking to detect cancer early, when it can be cured

Learn More Visit Site

Modulating RNA function by targeting regulatory proteins

Learn More Visit Site

Developing the leading range of first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections

Learn More Visit Site

Discovering and delivering innovative medical solutions and technology combined with digital health to help individuals suffering from pelvic floor disorders

Learn More Visit Site

Harnessing the link between the human gut microbiome and the central nervous system to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders.

Learn More Visit Site

Easing the burden of patients with severe endocrine disorders

Learn More Visit Site

Bringing innovation to the delivery of women’s healthcare

Learn More Visit Site

A novel innovation for Aesthetic Medicine

Learn More Visit Site

Creating a new generation of small molecule protease inhibitors

Learn More Visit Site

The leading dermatologist-recommended skin health cosmetics company

Learn More Visit Site

Developing oncology therapeutics that inhibit pathways critical to tumor growth and survival

Learn More Visit Site

Discovering and developing therapeutics that enhance mitochondrial functions

Learn More Visit Site

Minimally invasive solutions for the treatment of bone fractures

Learn More Visit Site

Developing therapies to improve the lives of patients diagnosed with cancer in ways that are truly meaningful

Learn More Visit Site

Focused on the discovery, development, and commercialization of proprietary small-molecule drugs

Learn More Visit Site

Improving nutritional status and pill burden in patients with pancreatic diseases

Learn More

Company Overview

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. Immunitas launched with a $39 million Series A round of financing from Longwood Fund, Leaps by Bayer, Novartis Venture Fund, Evotec, M Ventures, and Alexandria Venture Investments.

Read More Visit Site